



14<sup>th</sup> August 2019

The Secretary  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai 400 001

The Secretary  
The National Stock Exchange of India  
Limited  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block  
Bandra-Kurla Complex  
Bandra East,  
Mumbai 400 050

**Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)**

Dear Sirs

The unaudited financial results of the Company for the quarter and half year ended 30<sup>th</sup> June 2019 were approved by the Board of Directors of the Company at its meeting held on 29<sup>th</sup> July 2019 and published on 31<sup>st</sup> July 2019. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half

year ended 30<sup>th</sup> June 2019 in the format specified in the applicable accounting standards.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For SANOFI INDIA LIMITED

  
GIRISH FEKCHANDANI  
COMPANY SECRETARY

**SANOFI INDIA LIMITED**  
**Related Party Transactions for the half year ended 30th June 2019**

**Related Party Disclosures**

**i. Parties where control exists:**

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

**ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the year.**

Sanofi-Aventis Singapore Pte. Limited  
 Francopia S.A.R.L.  
 Sanofi-Aventis Deutschland GmbH  
 Sanofi-Aventis Groupe S.A.  
 Sanofi Lanka Limited  
 Sanofi-aventis U.S.Inc.  
 Sanofi Chimie S.A  
 Sanofi Pasteur India Private Limited  
 Sanofi-Synthelabo (India) Private Limited  
 Sanofi Winthrop Industrie S.A.  
 Sanofi-Aventis Pakistan Limited  
 Sanofi-Aventis Recherche et Développement S.A.  
 Sanofi-Aventis Spa  
 Shantha Biotechnics Private Limited  
 Sanofi India Limited Provident Fund

**iii. Key management personnel of the Company for the year**

Mr. Rajaram Narayanan - Managing Director  
 Mr. Ashwani Sood - Whole Time Director ( till the closure of business hours of May 31, 2019)  
 Mr. Charles Billard - Whole Time Director and CFO  
 Mr. Girish Tekchandani - Company Secretary

**iv. Non-Executive Directors**

Mr. Thomas Rouckout  
 Mr. Cyril Grandchamp-Desraux  
 Dr. Shailesh Ayyangar


**v. Independent Directors**

Mr. Aditya Narayan  
 Mr. Rangaswamy R. Iyer  
 Mrs. Usha Thorat

**vi. Transactions during the year**

(₹ in Million)

Particulars	June 30, 2019
<b>Ultimate Holding Company</b>	
Dividend paid	*
<b>Holding Company</b>	
Dividend paid	918
<b>Other related Parties</b>	
<b>Sale of Products</b>	
Sanofi-Aventis Singapore Pte. Limited	3,835
Others	303
<b>Total</b>	<b>4,138</b>
<b>Purchase of Raw Materials and Traded Goods</b>	
Sanofi-Aventis Singapore Pte. Limited	3,480
Others	8
<b>Total</b>	<b>3,488</b>
<b>Expenses recharged to other companies</b>	
Sanofi-Synthelabo (India) Private Limited	*
<b>Sale of Services</b>	
Sanofi-Synthelabo (India) Private Limited	592
Sanofi Pasteur India Private Limited	96
Sanofi Winthrop Industrie S.A.	69
Others	34
<b>Total</b>	<b>791</b>
<b>Rent Income</b>	
Sanofi-Synthelabo (India) Private Limited	4
<b>Loans repaid</b>	
Sanofi Pasteur India Private Limited	500
Mr. Ashwani Sood	*
<b>Total</b>	<b>500</b>
<b>Interest income on loans</b>	
Shantha Biotechnics Private Limited	210
Sanofi Pasteur India Private Limited	5
<b>Total</b>	<b>215</b>



Particulars	June 30, 2019
<b>Expenses recharged by other companies</b>	
Sanofi-Synthelabo (India) Private Limited	28
Sanofi Winthrop Industrie S.A.	10
Sanofi-Aventis Groupe S.A.	6
Others	5
<b>Total</b>	<b>49</b>
<b>Contribution to In-house Trust for Post Employment Benefits - Provident Fund</b>	
Sanofi India Limited Provident Fund #	138
<b>Payment towards Intangibles under development</b>	
Sanofi-Synthelabo (India) Private Limited	7
<b>Key Management Personnel Remuneration</b>	
<b>Remuneration</b>	
Mr. Rajaram Narayanan	19
Mr. Ashwani Sood	5
Mr. Charles Billard	9
Mr. Girish Tekchandani	6
<b>Total</b>	<b>39</b>
<b>Share based benefit</b>	
Mr. Rajaram Narayanan	6
Mr. Charles Billard	1
<b>Total</b>	<b>7</b>
<b>Sitting Fees to Independent Directors</b>	
Mr. Aditya Narayan	*
Mr. Rangaswamy R. Iyer	*
Ms. Usha Thorat	*
<b>Total</b>	<b>1</b>
<b>Commission to Independent Directors</b>	
Mr. Aditya Narayan	2
Mr. Rangaswamy R. Iyer	1
Ms. Usha Thorat	1
Mr. A. K. R. Nedungadi (upto January 15, 2018)	*
<b>Total</b>	<b>3</b>

\* denotes figure less than a million

# Including contribution by employees.

#### Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year six month ended June 30, 2019, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

#### vii. Outstanding as at June 30, 2019

(₹ in Million)

Particulars	June 30, 2019
Other related Parties	
<b>Trade Receivables</b>	
Sanofi-Aventis Singapore Pte. Limited	1,193
Sanofi-Synthelabo (India) Private Limited	109
Others	218
<b>Total</b>	<b>1,520</b>
<b>Trade Payables</b>	
Sanofi-Aventis Singapore Pte. Limited	1,148
Sanofi-Synthelabo (India) Private Limited	158
Others	7
<b>Total</b>	<b>1,313</b>
<b>Others Payables</b>	
Sanofi-Aventis Singapore Pte. Limited	36
<b>Total</b>	<b>36</b>
<b>Loans receivable</b>	
Shantha Biotechnics Private Limited#	4,450
Mr. Ashwani Sood *	*
<b>Total</b>	<b>4,450</b>

#Loans given to Shantha Biotechnics Private Limited at the rate of interest of 9.5% p.a.

Maximum balance outstanding during the year ₹ 4,450 Million

The said loans have been proposed to be utilized by Shantha Biotechnics Private Limited for business purpose.

The Loan have been given against corporate guarantee by Sanofi S.A. (Ultimate Holding Company). The Maturity Date of same is April 15, 2020.

\* Given as per the Company's policies for employee's

